Three Unmet Needs Defining HS Treatment
What the FSGS Market Shift Means for Commercial Strategy
After decades with no approved therapy, the FSGS treatment landscape is changing within a compressed window. Travere’s Filspari (sparsentan) is newly approved by the FDA as of April 13, 2026, [...]
What We Can Expect from the Next Wave of ATTR-CM Therapies
A continued trend towards earlier diagnosis and the potential impact of monoclonal antibodies are anticipated to reshape the market Historically underdiagnosed, transthyretin amyloidosis (ATTR) and ATTR-cardiomyopathy (ATTR-CM) have become [...]
Systemic Lupus Erythematosus (SLE): A Market in Transition
Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disorder marked by unpredictable organ involvement, clinical variability, and a high burden of chronic therapy. For biopharma teams evaluating opportunity in SLE, [...]
The Disease-Modifying Era in Angelman Syndrome
Why therapeutic window, and patient segmentation will become increasingly important in Angelman syndrome The Angelman syndrome (AS) treatment landscape is on the verge of a fundamental shift from symptomatic [...]
The Unyielding Unmet Need in Huntington’s: Why Pipeline Progress is Redefining Therapeutic Strategy
Gene therapies, shifting diagnosis paradigms, and a new calculus for patient eligibility are changing how companies must approach Huntington’s disease Huntington’s disease (HD) has long been recognized for its [...]
Why Tissue Type Matters Most in the Next Phase of DM1 Therapeutics
How multisystem involvement, patient heterogeneity, and new modalities are redefining the DM1 opportunity for drug developers Myotonic dystrophy type 1 (DM1) stands apart on the rare neuromuscular landscape as [...]
Why IgA Nephropathy Is Entering a New Commercial Phase
What evolving risk definitions, shifting treatment expectations, and B cell immunomodulation mean for drug developers IgA nephropathy (IgAN) is no longer a niche renal indication defined by slow progress and [...]
MARKETVUE® REPORT: More than half of STXBP1 Encephalopathy patients experience refractory seizures with currently available antiepileptics
Despite significant unmet need, there are currently no disease-modifying therapies available for the treatment of STXBP1 encephalopathy, although there are at least six assets in preclinical development, according to findings [...]